Stephen J Waters
Overview
Explore the profile of Stephen J Waters including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dings R, Van Laar E, Loren M, Webber J, Zhang Y, Waters S, et al.
Bioconjug Chem
. 2009 Dec;
21(1):20-7.
PMID: 20020769
Targeted delivery of therapeutic drugs promises to become the norm to treat cancer. Here, we conjugated the cytotoxic agent 6-hydroxypropylacylfulvene (HPAF) to anginex, a peptide that targets galectin-1, which is...
2.
Dings R, Van Laar E, Webber J, Zhang Y, Griffin R, Waters S, et al.
Cancer Lett
. 2008 Apr;
265(2):270-80.
PMID: 18378392
Combination of chemotherapeutic agents and angiogenesis inhibitors is now commonly employed in the clinic to treat cancer. Here, we used angiostatic agents anginex and 0118, in combination with the chemotherapeutic...
3.
Serova M, Calvo F, Lokiec F, Koeppel F, Poindessous V, Larsen A, et al.
Cancer Chemother Pharmacol
. 2005 Aug;
57(4):491-9.
PMID: 16075278
Purpose: This study assessed the cytotoxic effects of irofulven in combination with oxaliplatin and cisplatin in a panel of human cancer cell lines. Methods: Growth inhibition studies were performed using...
4.
Liang H, Salinas R, Leal B, Kosakowska-Cholody T, Michejda C, Waters S, et al.
Mol Cancer Ther
. 2004 Nov;
3(11):1385-96.
PMID: 15542777
Irofulven (hydroxymethylacylfulvene) is a novel antitumor drug, which acts by alkylating cellular macromolecular targets. The drug is a potent inducer of apoptosis in various types of tumor cells, whereas it...
5.
Woynarowski J, Woynarowska B, Trevino A, Salinas R, Herman T, Waters S, et al.
Cancer Biol Ther
. 2004 Oct;
3(11):1137-42.
PMID: 15467441
Unlike postmitotic cell death, direct premitotic apoptosis diminishes the risk of clonal selection and allows for the elimination of slowly growing cancer cells. This study characterized the ability to induce...
6.
Wang J, Wiltshire T, Wang Y, Mikell C, Burks J, Cunningham C, et al.
J Biol Chem
. 2004 Jul;
279(38):39584-92.
PMID: 15269203
Irofulven (6-hydroxymethylacylfulvene, HMAF, MGI 114) is one of a new class of anticancer agents that are semisynthetic derivatives of the mushroom toxin illudin S. Preclinical studies and clinical trials have...
7.
Van Laar E, Roth S, Weitman S, Macdonald J, Waters S
Anticancer Res
. 2004 Mar;
24(1):59-65.
PMID: 15015576
Background: Irofulven (MGI 114), a novel antitumor agent synthesized from the natural product illudin S, has a unique mechanism of action involving macromolecule adduct formation, S-phase arrest and induction of...
8.
Van Laar E, Weitman S, Macdonald J, Waters S
Prostate
. 2004 Mar;
59(1):22-32.
PMID: 14991863
Background: Irofulven (6-hydroxymethylacylfulvene, HMAF, MGI 114) is a novel antitumor agent currently undergoing clinical trials in hormone-refractory prostate cancer. This report examines the efficacy of irofulven alone or in combination...
9.
Poindessous V, Koeppel F, Raymond E, Cvitkovic E, Waters S, Larsen A
Int J Oncol
. 2003 Oct;
23(5):1347-55.
PMID: 14532976
Irofulven (6-hydroxymethylacylfulvene, MGI-114, NSC 683863) is a semisynthetic derivative of illudin S, a natural product obtained from the Omphalotus mushroom. Irofulven has demonstrated potent activity against a broad range of...
10.
Poindessous V, Koeppel F, Raymond E, Comisso M, Waters S, Larsen A
Clin Cancer Res
. 2003 Jul;
9(7):2817-25.
PMID: 12855662
Purpose: To characterize the activities of irofulven, a novelanticancer agent derived from the mushroom natural productilludin S toward human cancer cells. Experimental Design: We have determined the activity spectrum of...